In this video from Patient Power, CLL Program Director, Dr. Richard Furman discusses recent results on chronic lymphocytic leukemia (CLL) presented in abstracts during the 2015 meeting of the American Society of Hematology (ASH) and the place of newly targeted therapies including ABT-199 and ACP-196 in treating patients with CLL.
Dr. Furman has previously written about CLL abstracts from the 2015 ASH meeting here and here. More information about available CLL trials at Weill Cornell Medicine can be found on the Joint Clinical Trials website.